By end of 1998, the first European quality and safety requirements for in vitro diagnostic medical devices, the European Directive 98/79/EC (IVDD), stepped into effect. After almost 20 years in
A rapidly changing market, interdisciplinarity, and technological breakthroughs, such as CRISPR, mean companies must rapidly adapt to ensure their success or risk being left behind. Molecular diagnostics has revolutionized the healthcare decision-making process opening up unlimited opportunities for companies in molecular testing, next-generation sequencing, and development of medical devices. Tapping into our experience ensures your success.